Moderna Strengthens U.S. Manufacturing with New Onshore Drug Production

Moderna, Inc. is expanding its U.S. manufacturing capabilities by bringing drug product manufacturing to the Moderna Technology Center in Norwood, Massachusetts. This strategic move will allow Moderna to achieve full end-to-end manufacturing for its mRNA medicines domestically. The $140 million investment promises to create several hundred skilled biomanufacturing jobs, further boosting the local economy.

The initiative reflects Moderna's commitment to U.S.-based production, aiming to support both commercial and clinical supply needs while reinforcing the company's mRNA platform. Construction has commenced, with the project expected to be completed by mid-2027.

Moderna's mRNA technology gained significant recognition during its collaboration with the U.S. Government's Operation Warp Speed. The technology continues to drive potential advancements in several medical fields, including infectious diseases and cancer.